Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023960 | 0.85 | ALOX15 (0.55) | SMN1; SMN2ALOX15ATMMAPTTP53 | |
| SCHEMBL6479789 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2ALOX15ATMMAPTKDM4E | |
| SCHEMBL38664142 | 0.85 | ALOX15 (0.57) | SMN1; SMN2ALOX15ATMMAPTTP53 | |
| SCHEMBL6493316 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2ALOX15ATMMAPTKDM4E | |
| SCHEMBL10969560 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2ALOX15ATMMAPTTP53 | |
| SCHEMBL30034162 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2ALOX15ATMMAPTTP53 | |
| SCHEMBL8799913 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2ALOX15ATMMAPTTP53 | |
| SCHEMBL5851401 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2ALOX15ATMMAPTTP53 | |
| SCHEMBL20283874 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2ALOX15ATMMAPTTP53 | |
| SCHEMBL13104750 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2ALOX15ATMMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11912712-B2 | Organic electroluminescent element having an organic compound | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230286992-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC ELECTROLUMINESCENT ELEMENT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-11700768-B2 | Compound and organic light emitting device comprising the same | LG CHEM, LTD. (KR) | 2023-07-11 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20070238740-A1 | Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use | NITROMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-7262223-B2 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-28 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286992-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC ELECTROLUMINESCENT ELEMENT | SLCO4C1, SLCO1A2, SLCO2A1 | SMN1; SMN2 805/4885ALOX15 1609/4885ATM 3633/4885 |
| US-11700768-B2 | Compound and organic light emitting device comprising the same | ARL1, ARRB1, CRY1 | SMN1; SMN2 3394/4885ALOX15 1345/4885ATM 1312/4885 |
| US-11912712-B2 | Organic electroluminescent element having an organic compound | SLCO4C1, SLCO1A2, SLCO2A1 | SMN1; SMN2 869/4885ALOX15 1895/4885ATM 4036/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | SMN1; SMN2 2/4885ALOX15 4085/4885ATM 355/4885 |
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | ENTPD5, ENTPD1, NT5E | SMN1; SMN2 4189/4885ALOX15 1012/4885ATM 3148/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | SMN1; SMN2 1934/4885ALOX15 47/4885ATM 3465/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | SMN1; SMN2 4374/4885ALOX15 4703/4885ATM 150/4885 |
| US-20070238740-A1 | Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use | REN, ECE1, EDNRA | SMN1; SMN2 2836/4885ALOX15 261/4885ATM 4533/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | SMN1; SMN2 1908/4885ALOX15 42/4885ATM 3517/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | SMN1; SMN2 2211/4885ALOX15 2839/4885ATM 873/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | SMN1; SMN2 2701/4885ALOX15 491/4885ATM 2194/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | SMN1; SMN2 2078/4885ALOX15 2753/4885ATM 1516/4885 |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | SMN1; SMN2 19/4885ALOX15 1153/4885ATM 2868/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | SMN1; SMN2 4804/4885ALOX15 2239/4885ATM 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.